CRISPR genome-wide screening identifies PAK1 as a critical driver of ARSI cross-resistance in prostate cancer progression

Cancer statistics, 2022

Rebecca L. Siegel, Kimberly D. Miller, Hannah E. Fuchs et al. · CA A Cancer Journal for Clinicians · 2022 · 18.2K citations · Full text

Medicine, Oncology, Cancer Epidemiology +16

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

Emmanuel S. Antonarakis, Changxue Lu, Hao Wang et al. · New England Journal of Medicine · 2014 · 2.7K citations · Full text

Medicine, Oncology, Pharmacology +17

Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening

Julia Joung, Silvana Konermann, Jonathan S. Gootenberg et al. · Nature Protocols · 2017 · 1.3K citations · Full text

Life Sciences, Genetics, Molecular Biology +14

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer

Matthew R. Smith, Fred Saad, Simon Chowdhury et al. · New England Journal of Medicine · 2018 · 1.3K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer

Irfan A. Asangani, Vijaya L. Dommeti, Xiaoju Wang et al. · Nature · 2014 · 952 citations · Full text

Medicine, Oncology, Pharmacology +16